Articles: sars-cov-2.
-
Clinical features and outcomes of SARSCoV-2 infections may change between different waves of the pandemic. The objective of this study was to compare clinical characteristics and outcomes between two cohorts of patients hospitalized for COVID-19 during the first and second waves in Argentina. ⋯ Compared to patients admitted during the first wave, patients admitted with SARS-CoV2 during the second wave in Argentina were more seriously ill and had a higher mortality.
-
Internal medicine journal · Jan 2023
Symptom persistence and recovery among COVID-19 survivors during a limited outbreak in Canterbury, New Zealand: a prospective cohort study.
In Canterbury, near complete identification of coronavirus disease 2019 (COVID-19) cases during a limited outbreak provides unique insights into sequelae. ⋯ Persistent symptoms and longer recovery times were found in COVID-19 survivors, but not impaired generalised anxiety levels or HrQoL compared with COVID-19-uninfected participants.
-
This study aimed to investigate the effects of omega-3 fatty acid use on sepsis and mortality in patients treated for COVİD-19 disease in the intensive care unit (ICU) based on clinical and laboratory results. ⋯ Study results obtained in this study indicate that providing omega-3 fatty acid supplements may be beneficial to patients with severe COVİD-19, however further research with large-scale randomized controlled trials is necessary.
-
Clinicians and patients want to know the benefits and harms of outpatient treatment options for SARS-CoV-2 infection. ⋯ American College of Physicians. (PROSPERO: CRD42022323440).
-
Review Meta Analysis
Acute kidney injury in COVID-19 patients receiving remdesivir: A systematic review and meta-analysis of randomized clinical trials.
Remdesivir is an antiviral agent with positive effects on the prognosis of Coronavirus Disease (COVID-19). However, there are concerns about the detrimental effects of remdesivir on kidney function which might consequently lead to Acute Kidney Injury (AKI). In this study, we aim to determine whether remdesivir use in COVID-19 patients increases the risk of AKI. ⋯ Our study suggested that remdesivir treatment probably has little or no effect on the risk of AKI in COVID-19 patients.